Monoclonal Antibody Development Targeting IL-12 for Autoimmune Diseases

Cytokines play a pivotal role in the establishment and maintenance of autoimmune diseases. Numerous studies have established Interleukin (IL) 12 as an important factor for cell-mediated immunity. Equipped with world-leading technology platforms and professional scientific experts in the field of monoclonal antibody (mAb) development, Creative Biolabs offers top-quality anti-IL-12 antibody discovery and development services. Through our high-throughput systems, our clients could accelerate their research in autoimmune diseases with the most comprehensive view of anti-IL-12 antibodies.

IL-12 and Its Role in Autoimmune Diseases

IL-12 family is comprised of IL-12, IL-23, IL-27, and IL-35 and has emerged as important regulators of host immunity. IL-12 is the first member of the family and is comprised of IL-12p35 and IL-12p40. Although it is secreted by a variety of hematopoietic cell types, the major physiological producers are antigen-presenting cells (APCs), such as DCs and macrophages, during antigen presentation to naïve T-cells. The binding of IL-12 to its high-affinity receptor (IL-12Rβ1/IL-12Rβ2) expressed on activated T-cells, NK cells, and DCs activates tyrosine kinase 2 (TYK2), Janus kinases 2 (JAK2), and signal transducers and activators of transcription (STAT) pathways. Although STAT1, STAT3, and STAT4 are activated to varying extents in vitro, physiological responses to IL-12 are mediated mainly through STAT4. IL-12 induces naïve CD4+ T-cells to differentiate into Th1 cells. Th1 cells are implicated in the etiology of a number of human autoimmune diseases. Over the past decade, IL-12-driven Th1 cells were shown to be essential for the induction of autoimmune diseases, including autoimmune uveitis, multiple sclerosis (MS), rheumatoid arthritis (RA).

Fig.1 Main characteristics of members of the IL-12 family. (Nagai, 2010)

Anti-IL-12 Antibodies for the Treatment of Autoimmune Diseases

Pre-clinical studies highlight the role of IL-12 and IL-23 in the pathogenesis of psoriasis. The binding of IL-12 to the IL-12R on CD4+ T-cells results in differentiation to Th1, resulting in increased production of the pro-inflammatory cytokine IFN-γ. IL-23 binds to the IL-23R on CD4+ T-cells resulting in intracellular signaling for Th17 differentiation, which produces a multitude of cytokines, such as IL-17A, IL-17F, IL-26, IL-22, CCL20, IFN-γ, and TNF-α. Both IL-12 and IL-23 are heterodimers that share the same p40 subunit necessary for binding to their receptor. Therefore, the commonality of the p40 subunit is a therapeutic target for psoriasis, whereby inhibiting the p40 subunit impedes the downstream effects of IL-12 and IL-23.

mAb Development Targeting IL-12 at Creative Biolabs

Based on our advanced antigen-specific B lymphocytes sorting platform, hybridoma platform, and phage display platform for antibody development, Creative Biolabs focuses on developing high-specificity and high-affinity mAbs for research, diagnostic and therapeutic use. Our scientists are always dedicated to assisting our clients with the most satisfactory anti-IL-12 antibody development service to facilitate our clients' research in autoimmune diseases.

Highlights of Monoclonal Antibody Development Targeting IL-12

• Cutting-edge platforms for anti-IL12 antibody development
• A range of species available
• Top-rated customer experience
• Reliability and information security

Creative Biolabs has accumulated rich experience in antibody development for autoimmune diseases. We are confident to provide top-quality anti-IL-12 antibody development service. If you are interested in anti-IL-12 antibody discovery and development, please feel free to contact us for more details.

References

1. Ding, C.; et al. ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases. Current Opinion in Investigational Drugs. 2008;9(5):515-22.
2. Nagai, H.; et al. Antitumor activities of interleukin-27 on melanoma. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders). 2010, 10(1):41-6.

For Research Use Only | Not For Clinical Use